HER2 expression in cervical squamous cell carcinoma: high prevalence of HER2-low/ultralow and spatiotemporal heterogeneity across tumor evolution.

NPJ Precis Oncol · 2025 · PMC12753676 · PMID 41315811

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the HER2-ultralow subgroup did not reach statistical significance (mPFS 13.2 vs. 8.3 months; HR 0.78, 95% CI 0.50–1.21), the clinically meaningful improvement prompted FDA approval in January 2025 for HR+/HER2-low/ultralow metastatic breast cancer following progression on endocrine therapy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.